In addition, we provided two parallel analyses, with logistic and robust linear regression models, to allow the results’ comparison with the thresholds of minimal clinically important improvements in the DAS28-CRP and SDAI through robust linear regressions (see Figure 1 for details), while closely following the distribution of RA patients with in-remission/active disease in our sample through logistic regressions [27]. The gene discussed is CRP; the disease is rheumatoid arthritis.